


15/18
09.12.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of: Betenbaugh et al.

Application Serial No.: 09/930,440

Art Unit: 1652

Filed: August 16, 2001

Examiner: Manjunath N. Rao

For: Engineering Intracellular Sialylation Pathways

Atty. Docket No.: PF509P2

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Applicants hereby direct the Examiner's attention to references GG-GP listed on the attached revised Form PTO/SB/08A.

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in European Search Reports mailed June 10, 2002 and July 11, 2002, in connection with related international applications.

Applicants note that the Cite No. GK as provided by the European Patent Office (and stamped with identification code XP-002199519) shows the text and accession number for Medline/NLM accession NLM11384882 (relating to tibolone anabolic steroid). However, in the Partial European Search Report the document associated with identification code XP-002199519 shows an EMBL database accession no. AJ006215 (relating to CMP-N-acetylneuraminic acid synthetase). Applicants believe the reference to tibolone was probably errantly substituted for the reference to mouse CMP-N-acetylneuraminic acid synthetase. Applicants herewith enclose a copy of information

from EMBL Database Accession No. AJ006215; mouse CMP-N-acetylneuraminic acid synthetase (Cite No. GN on enclosed form PTO/SB/O8A).

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing of a first Office action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: September 3, 2002


Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5771

KKH/DAS/rmr